Back to results
US 2019/0241666 A1Published application
Antibody specifically binding to vegfr2
AssigneeAbclon Inc.
InventorsJong Seo LEE, Kyu Tae KIM, Bong Kook KO, Ki Hyun KIM, Hyun Jong LEE
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAbclon Inc.
InventorsJong Seo LEE, Kyu Tae KIM, Bong Kook KO, Ki Hyun KIM, Hyun Jong LEE
Estimating the term…
A novel antibody against VEGFR2 for use in the prevention or treatment of macular degeneration and cancer, which are angiogenesis-related diseases. The antibody of the present invention is an antibody which specifically binds to VEGFR2 which is overexpressed in vascular endothelial cells. The antibody of the present invention has very low homology compared to the CDR sequences of conventional VEGFR2 target antibodies, and thus is unique in its sequence. Since the antibody of the present invention, when treated alone, has the ability to inhibit vascular endothelial cell growth equivalent to that of ramucirumab which is conventionally used, it is very effective to prevent or treat angiogenesis-related diseases.
1-13. (canceled)
An antibody against vascular endothelial growth factor receptor 2 (VEGFR2) or an antigen binding fragment thereof, the antibody or antigen binding fragment thereof comprising:
Dependencies are inferred from the claim text.